Daxor Corporation (NASDAQ:DXR) Short Interest Update

Daxor Corporation (NASDAQ:DXR) was the recipient of a significant increase in short interest during the month of May. As of May 15th, there was short interest totaling 9,066 shares, an increase of 155.1% from the April 30th total of 3,554 shares. Based on an average trading volume of 12,397 shares, the days-to-cover ratio is currently 0.7 days. Approximately 0.4% of the company’s shares are short sold.

Daxor Stock Up 4.0%

Shares of DXR stock traded up $0.40 during trading hours on Friday, hitting $10.28. 1,671 shares of the company were exchanged, compared to its average volume of 7,882. The business has a 50 day moving average of $10.20 and a two-hundred day moving average of $11.87. Daxor has a 52 week low of $8.08 and a 52 week high of $14.76.

Daxor (NASDAQ:DXR) last issued its quarterly earnings data on Monday, March 2nd. The company reported ($0.10) earnings per share (EPS) for the quarter.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Lake Street Capital assumed coverage on shares of Daxor in a research note on Wednesday, February 11th. They issued a “buy” rating for the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Daxor in a research note on Friday, March 27th. One investment analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy”.

Institutional Investors Weigh In On Daxor

Large investors have recently made changes to their positions in the stock. Osaic Holdings Inc. bought a new stake in shares of Daxor during the second quarter worth $86,000. Crescent Grove Advisors LLC bought a new stake in shares of Daxor during the first quarter worth $104,000. Nano Cap New Millennium Growth Fund L P bought a new stake in shares of Daxor during the fourth quarter worth $184,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new stake in shares of Daxor during the first quarter worth $245,000. Finally, Aristides Capital LLC bought a new stake in shares of Daxor during the first quarter worth $403,000. Institutional investors own 1.34% of the company’s stock.

Daxor Company Profile

Daxor Corporation is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company’s core offering, the BVA‐100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient’s fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload.

In addition to the BVA‐100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting.